Blocking of the TGF-β signaling pathway induces browning of the white adipose tissue [36,37], and systematic blockade protects mice from obesity, diabetes and hepatic steatosis and thus may be a therapeutic strategy for obesity [36,37] and diabetes [36]. Here, TGFB1 is linked to fatty liver disease.